Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.72 |
| ▸ | MLKL | Q8NB16 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673705 | 1.00 | IDO1 (0.72) | IDO1MLKLCYP1A2ALDH1A1POLB | |
| SCHEMBL250817 | 1.00 | IDO1 (0.72) | IDO1MLKLCYP1A2ALDH1A1POLB | |
| SCHEMBL29537224 | 1.00 | IDO1 (0.72) | IDO1MLKLCYP1A2ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL29537578 | 0.98 | IDO1 (0.70) | IDO1MLKLCYP1A2ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL28705652 | 0.98 | IDO1 (0.70) | IDO1MLKLCYP1A2ALDH1A1POLB | |
| SCHEMBL15221577 | 0.85 | IDO1 (0.79) | IDO1MLKLALDH1A1POLBALOX12 | |
| SCHEMBL7101160 | 0.85 | IDO1 (0.79) | IDO1MLKLALDH1A1POLBALOX12 | |
| SCHEMBL4921708 | 0.84 | IDO1 (1.00) | IDO1MLKLALDH1A1POLBALOX12 | |
| SCHEMBL7946544 | 0.84 | IDO1 (0.78) | IDO1MLKLALDH1A1POLBALOX12 | |
| SCHEMBL2147079 | 0.84 | ALDH1A1 (0.66) | IDO1MLKLALDH1A1POLBALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | IDO1 2132/4885MLKL 3770/4885CYP1A2 743/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | IDO1 2028/4885MLKL 3835/4885CYP1A2 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.